Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects
Open accessThe DOI matches its Crossref record; 315 of the 315 references it cites were found in a registry or an index.
Abstract
Exposure to drugs during pregnancy has the potential to harm offspring. Teratogenic effects are the most feared adverse outcomes in newborns; however, a wide spectrum of less known, usually reversible and often acute, neonatal adverse events can also occur due to drug intake by mothers during pregnancy, particularly in close proximity to delivery. This narrative review is aimed at the description of drugs and drug classes for which licit maternal use in the predelivery period has been associated with neonatal non-teratogenic disorders. For each drug class, epidemiology, clinical features, biological mechanism and management of these adverse reactions have been discussed in detail. Although these adverse reactions have been described mainly for substances used illicitly for recreational purposes, several prescription drugs have also been involved; these include mainly psychotropic medications such as opioids, antidepressants, antiepileptics and antipsychotics. These effects can be partly explained by withdrawal syndromes (defined also as 'neonatal abstinence syndrome') caused by the delivery-related discontinuation of the drug disposition from the mother to the fetus, with symptoms that may include feeding disorders, tremors, irritability, hypotonia/hypertonia, vomiting and persistent crying, occurring a few hours to 1 month after delivery. Otherwise, neonatal neurological and behavioral effects can also be caused by a residual pharmacological effect due to an accumulation of the drug in the blood and tissues of the newborn, with various symptoms related to the toxic effects of the specific drug class, usually developing a few hours after birth. With few exceptions, validated protocols for the assessment and management of withdrawal or residual pharmacological effects of these drugs in neonates are often lacking or incomplete. Spontaneous reporting of these adverse reactions seems limited, although it might represent a useful tool for improving our knowledge about drug-induced neonatal syndromes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both neonatal BZD withdrawal and FIS typically present within the first hours of life and continue for up to 14 days.184”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [184]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Floppy infant syndrome (FIS)—which presents with hypotonia, lethargy, sucking difficulties, low Apgar score, hypothermia, apnea, cyanosis, hyperbilirubinemia, and CNS depression—has also been observed in newborns who have been exposed to BZDs in utero during the third trimester and may be a result of BZD toxicity.184,185”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [184]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
BRENNAN, F. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90430-3 · Cited by 1,129
Epidemiology of Puerperal Psychoses
Kendell, R. E., Chalmers, J. C., & Platz, C. (1987) · British Journal of Psychiatry · doi:10.1192/bjp.150.5.662 · Cited by 1,119
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Neonatal Abstinence Syndrome and Associated Health Care Expenditures: United States, 2000-2009
Patrick, S. W., Schumacher, R. E., Benneyworth, B. D., Krans, E. E., McAllister, J. M., & Davis, M. M. (2012) · JAMA · doi:10.1001/jama.2012.3951 · Cited by 907
Hudak, M. L., Tan, R. C., THE COMMITTEE ON DRUGS, THE COMMITTEE ON FETUS AND NEWBORN, Frattarelli, D. A. C., Galinkin, J. L., Green, T. P., Neville, K. A., Paul, I. M., Van Den Anker, J. N., et al. (2012) · Pediatrics · doi:10.1542/peds.2011-3212 · Cited by 877
Neonatal abstinence syndrome: assessment and management.
Finnegan, L. P., Connaughton, J. F., Kron, R. E., & Jp, E. (1975) · PubMed · Cited by 664
Kocherlakota, P. (2014) · Pediatrics · doi:10.1542/peds.2013-3524 · Cited by 612 · cited 6×
“In the most severe situations, pharmacological treatment can be required [2].”
BackgroundMethodInfluentialOberlander, T. F., Warburton, W., Misri, S., Aghajanian, J., & Hertzman, C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.898 · Cited by 551
Research works printed but not linked: 5
- 234. Gonzalez de Dios J, Moya-Benavent M, Carratala-Marco F. ["Floppy infant" syndrome in twins secondary to the use of benzodiazepines during pregnancy]. Revista de neurologia. 1999;29(2):121-3.
- 258. Taylor D, Paton, C., & Kapur, S. . Prescribing guidelines in psychiatry (11th ed.). CornWall, UK: A John Wiley & Sons. 2012.
- 284. S. B. Psychotropic Drug Directory. . Salisbury, UK: Fivepin Limited; . 2005;235.
- 285. Dev VJ KP. Adverse event profile and safety of clozapine. . Rev Contemp Pharmacother. 1995;6:197208.
- 286. Vavrusova L KM. Clozapine administration during pregnancy [in Czechoslovakian]. . Ceska Slov Psychiatr 1998;94:282-5.
Cited by
An advanced human in vitro co-culture model for translocation studies across the placental barrier
Aengenheister, L., Keevend, K., Muoth, C., Schönenberger, R., Diener, L., Wick, P., & Buerki-Thurnherr, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-23410-6 · Cited by 121
Neonatal Abstinence Syndrome: Update on Diagnostic and Therapeutic Strategies
Raffaeli, G., Cavallaro, G., Allegaert, K., Wildschut, E. D., Fumagalli, M., Agosti, M. A., Tibboel, D., & Mosca, F. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1954 · Cited by 69
“At delivery time, the decrease of serotonin transmission, as a consequence of both SNRI and SSRI discontinuation and receptor desensitization, has an impact on the other pathways involved.(29) For those neonates whose mothers use TCAs, withdrawal symptoms result from a “cholinergic overdrive phenomenon,” promoted by t…”
BackgroundInfluentialBrunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“184,185 Both neonatal BZD withdrawal and FIS typically present within the first hours of life and continue for up to 14 days.”
Umer, A., Loudin, S., Maxwell, S. R., Lilly, C. L., Stabler, M. E., Cottrell, L., Hamilton, C., Breyel, J., Mullins, C., & John, C. C. (2018) · Pediatric Research · doi:10.1038/s41390-018-0172-z · Cited by 26
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
“The onset and duration of symptoms correlate with the pharmacokinetics and placental disposition of benzodiazepines [227].”
Background
Metadata
- Authors
- Convertino, I., Sansone, A. C., Marino, A., Galiulo, M. T., Mantarro, S., Antonioli, L., Fornai, M., Blandizzi, C., & Tuccori, M.
- Affiliations
- University of Pisa (IT)
- Corresponding author
- Tuccori, Marco
- Venue
- Drug Safety
- Published
- 2016-10
- Volume
- 39
- Issue
- 10
- Pages
- 903-924
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2409304735
- Cited by
- 32
- References
- 315
- Citations by year
- 2025: 3 · 2024: 7 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 3
- FWCI
- 0.41
- Type
- journal article
- Language
- en
- Open access
- green
- link.springer.com
- Licence
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- Electronic Theses and Dissertations Repository (University of Pisa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- neonatal abstinence syndrome, withdrawal syndrome, psychotropic drugs, opioids, antidepressants, antiepileptic drugs, antipsychotic drugs, neonatal feeding disorders, adverse drug reaction reporting
- MeSH terms
- Adaptation, Physiological, Female, Humans, Infant, Newborn, Neonatal Abstinence Syndrome, Pregnancy, Psychotropic Drugs, Prescription Drugs, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. https://app.cochat.ai/papers/10.1007/s40264-016-0435-8
- The paper
- Convertino, I., Sansone, A. C., Marino, A., Galiulo, M. T., Mantarro, S., Antonioli, L., Fornai, M., Blandizzi, C., & Tuccori, M. (2016). Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. Drug Safety. https://doi.org/10.1007/s40264-016-0435-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.